demonstrated that IFN-AhR signaling in COVID-19 patients promoted mucins and the alveolar mucus contributed to hypoxia and inflammation; while inhibiting the AhR signaling resulted in improved lung function in a SARS-CoV-2 mouse model (102). The gene discussed is AHR; the disease is COVID-19.